20 unknown, 10 completed, 2 not yet recruiting, 1 recruiting. 33 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Unknown 20, Completed 10, Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow raltitrexed: new trials by email Literature Review of raltitrexed trials Research Report on raltitrexed
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC) - Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin | Phase 2 | Recruiting | Nanfang Hospital, Southern Medical University | 38 | 2025-12-25 | 2026-01-13 |
| CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC Ultrafractionated RT and CGA Guided systemic treatment., Ultrafractionated Radiotherapy, PD-1 antibody - Colon Cancer, Rectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 110 | 2024-11-01 | 2024-10-30 |
| CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC Ultrafractionated RT and CGA Guided systemic treatment., data prospectively collected, Ultrafractionated Radiotherapy - Colon Cancer, Rectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 124 | 2024-11-01 | 2024-10-28 |
| Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC Fruquintinib, S-1, raltitrexed - Fruquintinib, S-1 | Phase 2 | Unknown | Meng Qiu | 66 | 2023-02-20 | 2025-01-22 |
| The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer PD-1 antibody, Capecitabine, 5FU - Recurrent Rectal Cancer | Phase 2 | Unknown | Fudan University | 93 | 2022-11-30 | 2024-10-01 |
| Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy HAIC, Fruquintinib, Tislelizumab - Colorectal Cancer | Phase 2 | Unknown | Fudan University | 39 | 2022-07-12 | 2024-01-17 |
| Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients Regorafenib, Raltitrexed - Regorafenib, Raltitrexed | Phase 1 / Phase 2 | Unknown | China Medical University, China | 50 | 2022-07-01 | 2022-06-29 |
| SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer Raltitrexed, Irinotecan, Bevacizumab - Advanced Metastatic Colorectal Cancer | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 90 | 2021-11-12 | 2023-06-08 |
| Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer Fruquintinib and raltitrexed, Fruquintinib - Advanced Colorectal Carcinoma | Phase 2 | Unknown | Fudan University | 136 | 2020-09-28 | 2021-10-26 |
| A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer Raltitrexed, Cetuximab - Colorectal Cancer | Phase 2 | Unknown | Jiangsu Cancer Institute & Hospital | 50 | 2019-11-28 | 2021-08-30 |
| The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer raltitrexed for injection, nab-paclitaxel - Pancreatic Cancer, Chemotherapy Effect | Phase 2 | Unknown | Fudan University | 120 | 2019-11-01 | 2020-10-09 |
| Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia rhTPO, irinotecan, Raltitrexed - Recurrent Colorectal Carcinoma, Thrombopenia | Phase 2 | Unknown | Fudan University | 50 | 2019-02-01 | 2019-01-30 |
| RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study) Raltitrexed, Capecitabine - Colorectal Cancer | Phase 2 | Unknown | Shenzhen People's Hospital | 100 | 2019-01-28 | 2019-09-09 |
| A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer Radiotherapy Combined With Raltitrexed and Irinotecan - Recurrent Colorectal Cancer | Phase 2 | Unknown | Fudan University | 30 | 2019-01-01 | 2020-08-05 |
| Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus raltitrexed - Esophagus Squamous Cell Carcinoma | Phase 2 | Unknown | Huai'an First People's Hospital | 32 | 2018-09-05 | 2021-04-06 |
| Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer Raltitrexed, Irinotecan, Oxaliplatin - Advanced Colorectal Cancer | Phase 2 | Unknown | Jiangsu Cancer Institute & Hospital | 100 | 2017-02-15 | 2021-08-30 |
| Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection Raltitrexed, postoperative radiotherapy - Gastric Cancer | Phase 2 | Unknown | Zhongnan Hospital | 48 | 2017-01-01 | 2018-01-05 |
| Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients Irinotecan, Raltitrexed - ColoRectal Cancer | Phase 2 | Unknown | China Medical University, China | 100 | 2016-12-01 | 2017-02-14 |
| Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly Preoperative radiation, Raltitrexed, Pelvic surgery - Rectal Neoplasms Malignant | Phase 2 | Completed | Chinese Academy of Medical Sciences | 68 | 2016-09-01 | 2021-09-09 |
| Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer Raltitrexed and S-1 - Metastatic Colon Cancer | Phase 2 | Unknown | Fudan University | 82 | 2015-12-25 | 2017-10-02 |
Showing 20 of 33. Sign in to see all of them.
Colorectal Neoplasms (10) · Rectal Neoplasms (8) · Colonic Neoplasms (4) · Stomach Neoplasms (3) · Esophageal Squamous Cell Carcinoma (1) · Mesothelioma, Malignant (1) · Nasopharyngeal Carcinoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Thrombocytopenia (1)
Fudan University (11) · AstraZeneca (2) · China Medical University, China (2) · Chinese Academy of Medical Sciences (2) · Jiangsu Cancer Institute & Hospital (2) · Centre Georges Francois Leclerc (1) · Centro Nacional de Investigaciones Oncologicas CARLOS III (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Hebei Tumor Hospital (1) · Huai'an First People's Hospital (1) · Hubei Cancer Hospital (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Meng Qiu (1) · Nanfang Hospital, Southern Medical University (1) · National Cancer Institute, Naples (1)
China (22) · Spain (2) · France (1) · Italy (1) · Netherlands (1) · Turkey (Türkiye) (1)
Zhen Zhang, MD (2) · Ai Ping Zhou, Doctor of medcine (1) · Alessio G Morganti, Prof (1) · Antonio Avallone, M.D. (1) · Desheng Hu, M.D. (1) · Fuxiang Zhou, M.D. (1) · Giuseppe Giaccone, MD, PhD (1) · Jing Jin, MD (1) · Jinzhang Chen, Study Director (1) · Liangjun Zhu (1) · Meng Qiu, MD. (1) · Ruilian Xu, MD (1)
PMID 12187070, PMID 12196368, PMID 12565988, PMID 15083176, PMID 15865096, PMID 29946728, PMID 31999946, PMID 32645159, PMID 33567129, PMID 35235653, PMID 36101518, PMID 38053659, PMID 38773457, PMID 39223545, PMID 39286935, PMID 40022044, PMID 9006748
2008 (1)